The Value of Taurolidine Lock in Long Term Parenteral Nutrition
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Number of CVC infections
Study Overview
Brief Summary
Taurolidine alone or in combination with citrate have been proposed for locking the catheter to reduce the number of catheter infections. As there is not enough evidence to give recommendations in this regard, the study tested the hipothesis that taurolidine improves the outcome of long term paretneral nutrition.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Factorial
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •home parenteral nutrition for at least months before enrollment
- •presence of central venous cathter
Exclusion Criteria
- •home nutrition < 12 months
- •catheter in peripheral vein
Arms & Interventions
Control
Saline flush
Intervention: 2% Taurolidine Lock (Drug)
Control
Saline flush
Intervention: 1.35% Taurolidine (Drug)
2% Taurolidine lock
Catheter lock with 2% Taurolidine
Intervention: 2% Taurolidine Lock (Drug)
2% Taurolidine lock
Catheter lock with 2% Taurolidine
Intervention: 1.35% Taurolidine (Drug)
1.35% Taurolidine with citrate
Catheter lock with 1.35% Taurolidine + citrate
Intervention: 2% Taurolidine Lock (Drug)
1.35% Taurolidine with citrate
Catheter lock with 1.35% Taurolidine + citrate
Intervention: 1.35% Taurolidine (Drug)
Outcomes
Primary Outcomes
Number of CVC infections
Time Frame: 12 months
Number of central venous catheter infections
Secondary Outcomes
No secondary outcomes reported
Investigators
Stanislaw Klek
Assoc. Prof.
Stanley Dudrick's Memorial Hospital